Icon Plc (NASDAQ:ICLR) Receives $157.47 Consensus Price Target from Analysts

Icon Plc (NASDAQ:ICLR) has been given a consensus rating of “Hold” by the seventeen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $157.4667.

ICLR has been the topic of several analyst reports. Barclays increased their price target on Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Leerink Partners reaffirmed a “market perform” rating and set a $105.00 target price on shares of Icon in a report on Thursday, February 12th. Bank of America reiterated an “underperform” rating and set a $75.00 price target on shares of Icon in a research report on Thursday, February 12th. Weiss Ratings restated a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. Finally, Rothschild & Co Redburn set a $100.00 price objective on shares of Icon and gave the stock a “neutral” rating in a research note on Tuesday, February 17th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ICLR. Sanctuary Advisors LLC grew its position in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares during the period. Geneos Wealth Management Inc. boosted its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares in the last quarter. Spire Wealth Management boosted its position in Icon by 10.1% during the third quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock worth $119,000 after purchasing an additional 62 shares in the last quarter. New Wave Wealth Advisors LLC grew its holdings in Icon by 5.1% in the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 72 shares during the period. Finally, Signaturefd LLC increased its position in shares of Icon by 12.6% in the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after buying an additional 72 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Up 0.4%

NASDAQ:ICLR opened at $110.60 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company’s fifty day moving average price is $153.61 and its 200-day moving average price is $168.53. Icon has a 1-year low of $66.57 and a 1-year high of $211.00. The firm has a market capitalization of $8.93 billion, a P/E ratio of 14.97, a PEG ratio of 2.82 and a beta of 1.35.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.